Neuro. MS is meant to be used to diagnose and treat people with Multiple Sclerosis Drugs Development Market.
Brainomix has announced a new partnership with the French medical neurology imaging company Pixyl to include the latter’s multiple sclerosis (MS) treatment in its product line.
Neuro, Pixyl’s software-as-a-service (SaaS) solution, will be distributed by the company as part of the partnership agreement. MS.
The brain. The MS SaaS solution was created for MS patients’ diagnosis and treatment.
It provides clinicians and radiologists with clinically relevant information regarding neurological disorders like MS by utilizing cutting-edge deep learning technology.
Within five minutes, the solution automatically analyzes brain MRI images to identify, quantify, and track abnormalities.
Quantified measurements of lesion volumes and brain atrophy, as well as white matter hyperintensities that can be classified, are accessible through it.
Dr. Michalis Papadakis, co-founder and CEO of Brainomix, stated: We are thrilled to begin this partnership with Pixyl, a company with which we share a common vision for the creation of cutting-edge AI-powered diagnostic and treatment decision-making tools.
“As a means of providing our customers with a broader range of AI-enabled solutions, we recognized that there was an opportunity to form these kinds of third-party technology partnerships.
Our e-Stroke platform has been extremely successful, and we now plan to apply that knowledge to Pixyl’s Neuro. MS SaaS solution, which aids in expanding the use of this leading-edge technology in clinical settings.
The company will only sell Pixyl’s SaaS solution in important markets in Eastern Europe, the United States, the Nordics, and Ireland.
The Neuro is a Class IIA product with CE mark approval. In addition to the company’s e-Stroke platform, a comprehensive stroke imaging solution, the MS solution will be made available to the company’s existing clientele.
